نتایج جستجو برای: factor eight inhibitor bypassing activity
تعداد نتایج: 2125544 فیلتر نتایج به سال:
Acquired hemophilia A (AHA) is a rare, potentially life-threatening hemorrhagic disorder that presents a complex clinical challenge. The immune-mediated production of autoantibodies, known as factor VIII inhibitors, often results in clinically significant soft tissue or post-procedural bleeding episodes in patients without a previous diagnosis of a bleeding disorder. Acquired antibodies against...
Background: Factor VIII administration to hemophilia A patients results in an immune response (inhibitor formation) which significantly complicates the therapy. The present study was performed to determine the prevalence of inhibitor development in hemophilia A patients receiving recombinant factor VIII therapy. Materials and Methods: This was an observational descriptive study. Clotting fac...
a study of factor structure of the mood disorder questionnaire in a sample of iranian pregnant women
ôbjective: the mood disorder questionnaire (mdq) has been developed as a self-reporting, brief, and easy-to-use screening instrument to improve identification of bipolar mood disorders. the goals of the present study were to examine the prevalence of this disorder and interrelationship of its symptoms by factor analysis of mdq in a group of pregnant women in ïran. methods: ône thousand and eigh...
In this issue of Blood, Weeterings and colleagues report that binding to the GPIb/ IX/V complex plays a role in mediating the platelet surface procoagulant effects of rFVIIa. I n 1997, our first article on the mechanism of action of recombinant activated factor VII (rFVIIa) in hemophiliacs 1 was summarily rejected by Blood because the reviewers felt that the topic was not of interest to a gener...
Acquired coagulation factor inhibitor is a rare coagulation disorder. We herein report a patient with acquired factor V inhibitor showing a decrease in multiple coagulation factor activities. A high titer of factor V inhibitor presumably led to a marked inhibition of factor V activity in the specific factor-deficient plasma used in coagulation factor activity assays based on either an activated...
background: factor viii administration to hemophilia a patients results in an immune response (inhibitor formation) which significantly complicates the therapy. the present study was performed to determine the prevalence of inhibitor development in hemophilia a patients receiving recombinant factor viii therapy. materials and methods: this was an observational descriptive study. clotting factor...
FEIBA (factor eight inhibitor by-passing activity) Immuno was used to achieve hemostasis in 46 patients with factor VIII inhibitors with titers greater than 4 Bethesda units, and 3 patients with factor IX inhibitors. One-hundred and sixty-five bleeding episodes were treated with 50-70 U/kg; 102 of these episodes occurred in joints. 20 in mucous membranes, 33 muscle and soft tissue, and 10 were ...
The development of inhibitor antibodies that bind to active sites on the factor VIII (FVIII) molecule and neutralize its function and/or accelerate its clearance is the most serious adverse event and safety issue associated with the treatment of hemophilia A. Inhibitor development complicates hemostasis management and increases morbidity and the cost of treatment because bleeding episodes do no...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید